| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
The molecular targets of NSC 409012 are not fully characterized, but as a rhodanine derivative, it may interact with various enzymes and proteins through its rhodanine core and iodobenzylidene substituent. The compound has been reported to regulate gene expression, cell proliferation, and apoptosis. The anti-inflammatory activity suggests it may modulate inflammatory pathways, potentially through the inhibition of pro-inflammatory cytokines or the NF-κB pathway. The anti-tumor activity suggests it may inhibit cell proliferation or induce apoptosis in cancer cells. The antioxidant activity suggests it may scavenge reactive oxygen species or upregulate antioxidant defense enzymes. The antifungal activity suggests it may target essential fungal enzymes or cellular processes. Rhodanine derivatives are known to inhibit various enzymes, including aldose reductase, topoisomerases, and kinases. Specific target identification for NSC 409012 would require further experimental studies using biochemical and cell-based assays.
|
|---|---|
| ln Vitro |
In vitro activity of NSC 409012 is characterized by its anti-inflammatory, anti-tumor, antioxidant, and antifungal activities. In anti-inflammatory assays, NSC 409012 reduces the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in LPS-stimulated macrophages and inhibits NF-κB activation. In anti-tumor assays, the compound inhibits the proliferation of various cancer cell lines, with IC50 values expected in the micromolar range. The compound induces apoptosis and cell cycle arrest in cancer cells. In antioxidant assays, NSC 409012 scavenges free radicals and protects cells from oxidative damage. In antifungal assays, the compound inhibits the growth of various fungal species, with MIC values expected in the micromolar range. The compound's effects on gene expression, cell proliferation, and apoptosis are assessed by qRT-PCR, Western blotting, and flow cytometry. Specific IC50 and MIC values for NSC 409012 are not provided in the available literature, and further studies would be needed to fully characterize its in vitro activity profile.
|
| ln Vivo |
In vivo activity of NSC 409012 has not been extensively reported in the available literature. As a bioactive compound with anti-inflammatory, anti-tumor, antioxidant, and antifungal activities, NSC 409012 would be expected to show efficacy in animal models of inflammation, cancer, oxidative stress, and fungal infection. In models of inflammation, the compound would be expected to reduce edema, inflammatory cell infiltration, and cytokine levels. In models of cancer, NSC 409012 would be expected to inhibit tumor growth and improve survival. In models of oxidative stress, the compound would be expected to reduce oxidative damage and protect tissues. In models of fungal infection, the compound would be expected to reduce fungal loads and improve survival. The compound's in vivo efficacy would depend on its pharmacokinetic properties, including oral bioavailability, tissue distribution, and metabolic stability. Specific in vivo data are not provided in the available literature, and further studies would be needed to evaluate the compound's therapeutic potential.
|
| Additional Infomation |
NSC 409012 (CAS# 90947-00-5) is an active compound (5-(4-iodobenzylidene)rhodanine) with anti-inflammatory, anti-tumor, antioxidant, and antifungal activities. It has a molecular formula of C10H6INOS2 and a molecular weight of 347.2 g/mol. Future research could focus on identifying the molecular targets of NSC 409012, optimizing its biological activities through structural modifications, evaluating its in vivo efficacy in animal models, and developing it as a potential therapeutic for inflammatory, neoplastic, and infectious diseases.
|
| Molecular Formula |
C10H6INOS2
|
|---|---|
| Molecular Weight |
347.2
|
| Exact Mass |
346.894
|
| CAS # |
90947-00-5
|
| PubChem CID |
5763629
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.99g/cm3
|
| Index of Refraction |
1.805
|
| LogP |
3.108
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
321
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C(=CC2C=CC(I)=CC=2)SC(=S)N1
|
| InChi Key |
LIRUBCDZKKWCPS-YVMONPNESA-N
|
| InChi Code |
InChI=1S/C10H6INOS2/c11-7-3-1-6(2-4-7)5-8-9(13)12-10(14)15-8/h1-5H,(H,12,13,14)/b8-5-
|
| Chemical Name |
(E)-5-(4-Iodobenzylidene)-2-thioxothiazolidin-4-one
|
| Synonyms |
NSC-409012NSC409012NSC 409012
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8802 mL | 14.4009 mL | 28.8018 mL | |
| 5 mM | 0.5760 mL | 2.8802 mL | 5.7604 mL | |
| 10 mM | 0.2880 mL | 1.4401 mL | 2.8802 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
